Skip to Main Content

It’s time to reconsider and maybe revoke the approval of Acadia Pharmaceuticals’ (ACAD) antipsychotic drug Nuplazid.

The San Diego-based drug maker has run four randomized, placebo-controlled Phase 3 clinical trials of Nuplazid and managed to demonstrate a statistically significant reduction in hallucinations and psychotic symptoms in only one of them. 


Three of these clinical trials failed, including a study involving schizophrenia patients that Acadia announced on Monday night. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!